Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies